Considering the significant impact of genomic and immune profiles on therapeutic efficacy, the present study provides the largest cohort of Chinese patients with GC to depict the genomic and immune landscapes and their correlations with HER2 amplification and PD‐L1 expression. This evidence concerns the gene ERBB2 and gastric cancer.